Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421

C

Children's Oncology Group

Status

Completed

Conditions

Leukemia

Treatments

Genetic: proteomic profiling
Genetic: microarray analysis
Other: laboratory biomarker analysis
Genetic: gene expression analysis

Study type

Observational

Funder types

NETWORK
NIH

Identifiers

NCT01035307
AAML09B2
CDR0000659560 (Other Identifier)
COG-AAML09B2 (Other Identifier)
NCI-2011-02201 (Registry Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at biomarkers in tissue samples from young patients with acute myeloid leukemia previously enrolled on clinical trial POG-9421.

Full description

OBJECTIVES: To profile basal and potentiated phospho-protein networks (PPPNs) using tissue samples from pediatric patients with de novo acute myeloid leukemia (AML) previously enrolled on clinical trial POG-9421. To classify AML-based signal transduction mechanisms. To correlate profiles of basal and PPPNs with specific molecular lesions (e.g., FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and profiles of gene expression in tumor tissue samples. OUTLINE: Banked tissue samples are collected for laboratory studies, including phospho-protein signaling and gene expression profiling studies.

Enrollment

90 estimated patients

Sex

All

Ages

Under 20 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

Diagnosis of acute myeloid leukemia, meeting 1 of the following criteria:

  • Primary induction failure (i.e., failed to achieve remission within the first 60 days of therapy)
  • Relapsed disease (early or late)
  • In continuous complete remission
  • Previously enrolled on POG-9421
  • Tissue samples available

PATIENT CHARACTERISTICS:

Not specified

PRIOR CONCURRENT THERAPY:

See Disease Characteristics

Trial design

90 participants in 1 patient group

Genomic and Proteomic Profiling
Treatment:
Other: laboratory biomarker analysis
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: proteomic profiling

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems